These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34559006)

  • 41. Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma.
    Goksel S; Ilkkilic K; Bulbul O; Akdogan E
    Nucl Med Commun; 2022 Oct; 43(10):1077-1083. PubMed ID: 36006402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
    Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment response evaluation with
    Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of an artificial intelligence-based tool in [
    Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How do we image patients with multiple myeloma and precursor states?
    Chakraborty R; Hillengass J; Lentzsch S
    Br J Haematol; 2023 Nov; 203(4):536-545. PubMed ID: 37217164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
    Nanni C; Zamagni E; Farsad M; Castellucci P; Tosi P; Cangini D; Salizzoni E; Canini R; Cavo M; Fanti S
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):525-31. PubMed ID: 16453155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study.
    Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA
    Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of [
    Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
    Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation.
    Ripani D; Caldarella C; Za T; Pizzuto DA; Rossi E; De Stefano V; Giordano A
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):116-128. PubMed ID: 30054697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
    Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
    Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemokine receptor-4 targeted PET/CT with
    Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whole-body three-dimensional short tau inversion recovery and T1-weighted in/opposed phase MRI in the detection of neuroblastoma bone marrow metastasis: comparative study with PET/CT utilising bone marrow biopsy as the reference standard.
    Soliman H; El-Noueam K; Ettaby A; Fadel S; Abougabal AM
    Clin Radiol; 2023 Jul; 78(7):e535-e541. PubMed ID: 36997373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: comparison with skeletal scintigraphy and FDG PET/CT.
    Kumar J; Seith A; Kumar A; Sharma R; Bakhshi S; Kumar R; Agarwala S
    Pediatr Radiol; 2008 Sep; 38(9):953-62. PubMed ID: 18636251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of
    Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
    Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
    Ak İ; Onner H; Akay OM
    Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
    Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
    Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT.
    Yoon JH; Lee JM; Chang W; Kang HJ; Bandos A; Lim HJ; Kang SY; Kang KW; Ryoo SB; Jeong SY; Park KJ
    Radiology; 2020 Feb; 294(2):310-319. PubMed ID: 31793850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [
    Azad GK; Taylor BP; Green A; Sandri I; Swampillai A; Harries M; Kristeleit H; Mansi J; Goh V; Cook GJR
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):821-830. PubMed ID: 30506455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.